Q-omics provides the consensus-scored TEX37 profile across patient tissues and cancer cell-line models. TEX37 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, TEX37 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, TEX37 RNA expression shows 7,885 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight CHOL, HNSC, and TGCT as cancer lineages where TEX37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX37 survival associations across molecular data types. TEX37 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX37 RNA expression–survival associations across cancer types. High TEX37 expression shows unfavorable associations in CHOL, UVM, UCEC, LUSC and BRCA, but favorable associations in OV. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for TEX37 RNA expression.
This table summarizes TEX37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TEX37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX37 shows higher tumor expression in HNSC, LIHC, LUSC, BLCA, LUAD and PRAD. The HNSC box plot shows higher TEX37 RNA expression in tumor versus normal tissue (log2 FC = +0.079, t-test p = .002).
This table shows molecular features associated with TEX37 in patient tissues and cancer cell lines. In patient samples, TEX37 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX37 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
